BR112023019496A2 - Derivados de ciclobutila 1,3-substituída e usos dos mesmos - Google Patents

Derivados de ciclobutila 1,3-substituída e usos dos mesmos

Info

Publication number
BR112023019496A2
BR112023019496A2 BR112023019496A BR112023019496A BR112023019496A2 BR 112023019496 A2 BR112023019496 A2 BR 112023019496A2 BR 112023019496 A BR112023019496 A BR 112023019496A BR 112023019496 A BR112023019496 A BR 112023019496A BR 112023019496 A2 BR112023019496 A2 BR 112023019496A2
Authority
BR
Brazil
Prior art keywords
substituted cyclobutyl
present
derivatives
cyclobutyl derivatives
disorders
Prior art date
Application number
BR112023019496A
Other languages
English (en)
Inventor
Donglei Liu
J Powers James
Julien Papillon
Stefan Peukert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112023019496A2 publication Critical patent/BR112023019496A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

derivados de ciclobutila 1,3- substituída e usos dos mesmos. a presente invenção refere-se a compostos e composições farmacêuticas úteis para o tratamento de doenças ou distúrbios mediados pelo receptor trpv1. a presente invenção também fornece métodos de tratamento de doenças ou distúrbios oculares administrando-se a um indivíduo que precisa dos mesmos uma quantidade terapeuticamente eficaz de um composto da fórmula (i) ou uma composição farmacêutica descrita no pre-sente documento.
BR112023019496A 2021-03-26 2022-03-24 Derivados de ciclobutila 1,3-substituída e usos dos mesmos BR112023019496A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163166289P 2021-03-26 2021-03-26
PCT/IB2022/052720 WO2022201097A1 (en) 2021-03-26 2022-03-24 1,3-substituted cyclobutyl derivatives and uses thereof

Publications (1)

Publication Number Publication Date
BR112023019496A2 true BR112023019496A2 (pt) 2023-12-05

Family

ID=80999265

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019496A BR112023019496A2 (pt) 2021-03-26 2022-03-24 Derivados de ciclobutila 1,3-substituída e usos dos mesmos

Country Status (14)

Country Link
US (1) US11845730B2 (pt)
EP (1) EP4313951A1 (pt)
JP (1) JP2024510778A (pt)
KR (1) KR20230162660A (pt)
CN (1) CN117062804A (pt)
AR (1) AR125196A1 (pt)
AU (1) AU2022244467A1 (pt)
BR (1) BR112023019496A2 (pt)
CA (1) CA3214066A1 (pt)
IL (1) IL307189A (pt)
MX (1) MX2023011377A (pt)
TW (1) TW202304864A (pt)
UY (1) UY39681A (pt)
WO (1) WO2022201097A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024062389A1 (en) * 2022-09-21 2024-03-28 Bausch + Lomb Ireland Limited Crystalline polymorph forms of a trpv1 antagonist and formulations thereof
US20240148709A1 (en) * 2022-11-08 2024-05-09 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
CN101489989A (zh) * 2006-07-13 2009-07-22 协和发酵麒麟株式会社 戊二烯酰胺衍生物
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
DE102010052781A1 (de) * 2010-11-30 2012-05-31 Trw Automotive Gmbh Befestigungsvorrichtung und Befestigungsbaugruppe zur Befestigung eines Gasgenerators und Fahrzeuginsassenrückhaltesystem
TW201302681A (zh) * 2011-03-25 2013-01-16 Abbott Lab Ｔｒｐｖ１拮抗劑
JP2014510768A (ja) * 2011-04-11 2014-05-01 グラクソ グループ リミテッド Ｔｒｐｖ１アンタゴニストとしてのｎ−シクロブチルイミダゾピリジンメチルアミン
US9747862B2 (en) 2015-11-02 2017-08-29 Castar, Inc. Method of immersive rendering for wide field of view
US10269906B2 (en) * 2016-11-30 2019-04-23 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device having two spacers
WO2018151678A1 (en) * 2017-02-15 2018-08-23 Agency For Science, Technology And Research Compounds for treatment of cancer and epigenetics
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AU2019392904B9 (en) 2018-12-07 2022-12-22 University Of Maryland, Baltimore Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors

Also Published As

Publication number Publication date
US20220324811A1 (en) 2022-10-13
CA3214066A1 (en) 2022-09-29
AU2022244467A1 (en) 2023-10-12
WO2022201097A1 (en) 2022-09-29
AR125196A1 (es) 2023-06-21
TW202304864A (zh) 2023-02-01
EP4313951A1 (en) 2024-02-07
JP2024510778A (ja) 2024-03-11
MX2023011377A (es) 2023-10-06
KR20230162660A (ko) 2023-11-28
CN117062804A (zh) 2023-11-14
UY39681A (es) 2022-10-31
US11845730B2 (en) 2023-12-19
IL307189A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
BR112023019496A2 (pt) Derivados de ciclobutila 1,3-substituída e usos dos mesmos
JOP20210017A1 (ar) مثبطات جسيم التهابي nlrp3
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
MA45223B1 (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
BR0308784A (pt) Miméticos de glucocorticóides, métodos para fabricar os mesmos, composições farmacêuticas e usos dos mesmos
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
CR20230256A (es) Compuestos farmacéuticos
BR112022024120A2 (pt) Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR112023002957A2 (pt) Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
BR112022009942A2 (pt) Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado
BR112021011325A2 (pt) Derivados de rapamicina
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
MX2023006578A (es) Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas.
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
BR112022018173A2 (pt) Composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, composto para o uso e uso de um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo
CL2021000282A1 (es) Inhibidores de ckd8/19
BR112022018504A2 (pt) Usos de uma composição
BR112022014278A2 (pt) Conjugados de composto proteico-antiviral
BR0318533A (pt) azolidinacarbonitrilas e seu uso como inibidores de dpp-iv
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
BR112023017040A2 (pt) Derivados de indolina como inibidores de ddr1 e ddr2
MX2023012442A (es) Inhibidores de la ferroportina modificados.